Volume | 347,149 |
|
|||||
News | - | ||||||
Day High | 1.49 | Low High |
|||||
Day Low | 1.28 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioRestorative Therapies Inc | BRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.33 | 1.28 | 1.49 | 1.46 | 1.37 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,077 | 347,149 | $ 1.41 | $ 491,009 | - | 1.20 - 7.13 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:17:41 | 40 | $ 1.47 | USD |
BioRestorative Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.87M | 4.71M | - | 146k | -14.42M | -3.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioRestorative Therapies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.23 | 1.55 | 1.21 | 1.42 | 3,622,626 | 0.17 | 13.82% |
1 Month | 1.34 | 1.65 | 1.21 | 1.38 | 1,531,985 | 0.06 | 4.48% |
3 Months | 1.40 | 1.65 | 1.20 | 1.37 | 607,712 | 0.00 | 0.00% |
6 Months | 1.85 | 3.6699 | 1.20 | 2.07 | 490,295 | -0.45 | -24.32% |
1 Year | 4.14 | 7.13 | 1.20 | 2.21 | 268,973 | -2.74 | -66.18% |
3 Years | 8.90 | 8.90 | 1.20 | 3.27 | 225,501 | -7.50 | -84.27% |
5 Years | 8.90 | 8.90 | 1.20 | 3.27 | 225,501 | -7.50 | -84.27% |
BioRestorative Therapies Description
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |